Immunovant Statistics

Total Valuation

Immunovant has a market cap or net worth of $4.00 billion. The enterprise value is $3.48 billion.

Market Cap	4.00B
Enterprise Value	3.48B

Important Dates

The last earnings date was Monday, November 10, 2025, before market open.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunovant has 175.28 million shares outstanding. The number of shares has increased by 12.85% in one year.

Current Share Class	175.28M
Shares Outstanding	175.28M
Shares Change (YoY)	+12.85%
Shares Change (QoQ)	+1.62%
Owned by Insiders (%)	0.67%
Owned by Institutions (%)	49.50%
Float	67.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	7.67
P/TBV Ratio	7.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.07

Current Ratio	9.07
Quick Ratio	8.28
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -95.93% and return on invested capital (ROIC) is -62.85%.

Return on Equity (ROE)	-95.93%
Return on Assets (ROA)	-55.42%
Return on Invested Capital (ROIC)	-62.85%
Return on Capital Employed (ROCE)	-93.73%
Revenue Per Employee	n/a
Profits Per Employee	-$1.28M
Employee Count	362
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immunovant has paid $2.24 million in taxes.

Income Tax	2.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.92% in the last 52 weeks. The beta is 0.56, so Immunovant's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-19.92%
50-Day Moving Average	20.77
200-Day Moving Average	17.43
Relative Strength Index (RSI)	52.41
Average Volume (20 Days)	1,286,695

Short Selling Information

The latest short interest is 16.38 million, so 9.35% of the outstanding shares have been sold short.

Short Interest	16.38M
Short Previous Month	16.21M
Short % of Shares Out	9.35%
Short % of Float	24.19%
Short Ratio (days to cover)	8.36

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-487.11M
Pretax Income	-462.44M
Net Income	-464.69M
EBITDA	-486.69M
EBIT	-487.11M
Earnings Per Share (EPS)	-$2.82

Full Income Statement

Balance Sheet

The company has $521.87 million in cash and n/a in debt, giving a net cash position of $521.87 million or $2.98 per share.

Cash & Cash Equivalents	521.87M
Total Debt	n/a
Net Cash	521.87M
Net Cash Per Share	$2.98
Equity (Book Value)	519.71M
Book Value Per Share	2.98
Working Capital	510.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$430.95 million and capital expenditures -$381,000, giving a free cash flow of -$431.34 million.

Operating Cash Flow	-430.95M
Capital Expenditures	-381,000
Free Cash Flow	-431.34M
FCF Per Share	-$2.46

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.85%
Shareholder Yield	-12.85%
Earnings Yield	-11.61%
FCF Yield	-10.77%

Dividend Details

Analyst Forecast

The average price target for Immunovant is $27.71, which is 21.32% higher than the current price. The consensus rating is "Buy".

Price Target	$27.71
Price Target Difference	21.32%
Analyst Consensus	Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2